Form 4: Ironwood Pharmaceuticals Director Catherine Moukheibir Reports Stock Award and Disposal

Director Catherine Moukheibir reports acquisition of restricted stock and disposal of shares to cover taxes.

Summary

• On June 18, 2024, Catherine Moukheibir, a director of Ironwood Pharmaceuticals, reported a transaction involving the company's Class A Common Stock.
• Moukheibir acquired 24,311 shares of restricted stock at $0 per share.
• Simultaneously, Moukheibir disposed of shares to cover tax obligations, resulting in her holding 72,944 shares following the reported transactions.
• The restricted stock vests fully on the date immediately preceding the next annual meeting of stockholders, as per the Second Amended and Restated Non-employee Director Compensation Policy effective January 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a director. The acquisition of restricted stock is generally viewed positively as it aligns the director's interests with shareholders, but the disposal of shares to cover taxes is a standard practice.

Positives

• The grant of restricted stock to a director aligns their interests with those of the shareholders.
• The director's continued holding of a significant number of shares (72,944) indicates confidence in the company.

Future Outlook

The restricted stock vests fully on the date immediately preceding the next annual meeting of stockholders.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders can monitor insider transactions to assess management's confidence in the company.
• The stock transactions have a minor impact on the overall shareholding structure.

Key Dates